Boston Immune Technologies And Therapeutics Inc.
Winchester, MA · Biotech · Private
BITT-1492, a monoclonal antibody antagonist against TNFR2 for cancer immunotherapy
bostonimmunetech.com →- Grants
- $10M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | $397,959 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | $1,221,684 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | $1,221,684 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | $298,049 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | $298,049 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy | $776,973 | |
| Federal grant | Department of Health and Human Services · Phase II · Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | $1,565,481 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | $926,858 | |
| Federal grant | Department of Health and Human Services · Phase II · Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | $2,409,283 | |
| Federal grant | Department of Health and Human Services · Phase II · Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome. | $990,243 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1645 | CANCER TARGETED TECHNOLOGY, LLC | — | — |
| 1646 | IMMUNARTES LLC | — | — |
| 1647 | GENERAL NUTRACEUTICAL TECHNOLOGY LLC | — | — |
| 1648 | Boston Immune Technologies And Therapeutics Inc. | — | — |
| 1649 | Respana Therapeutics, Inc | — | — |
| 1650 | Seawolf Therapeutics | — | — |
| 1651 | KARIS BIO USA, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.